 In situ active compound assembly |
| I claim: 1. A method to modify a target condition contained within an environment with a conjugate ... |
|
| Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
| The invention is directed to a method for the prophylaxis or treatment of an animal for systemic ... |
|
| Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor |
| We claim: 1. A compound having the structural formula I ##STR4## wherein R is cyano, ##STR5## --C(.... |
|
| Antioxidant-induced apoptosis in vascular smooth muscle cells |
| The invention is based on the discovery that, unlike other cell types, vascular smooth muscle cells ... |
|
| Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
| In a method aspect, this invention relates to a method of treating the climacterium symptoms in a ... |
|
| Microbial hair tonic composition |
| We claim: 1. A microbial hair treatment composition comprising 10.sup.6 to 10.sup.8 cells/ml of ... |
|
| Hair treating composition |
| OF THE INVENTION The formulation of 9 parts d-panthenyl ethyl ether and 1 part d-panthenol can be ... |
|
|
Substituted and bridged pyridines useful as calcium channel blockers
| Details |
Inventors: Hartman, George D.; Phillips, Brian T.;
Assignee: Merck & Co., Inc. (Rahway, NY)
Primary Examiner:
Assistant Examiner:
Attorney, Agent or Firm:
Novel substituted and bridged pyridine compounds useful as calcium channel blockers, pharmaceutical compositions thereof, and methods of treatment are disclosed. |
|
DETAILED DESCRIPTION OF THE INVENTION The specific substituted and bridged pyridine compounds of this invention are represented by the following general structural formula (I): ##STR1## wherein: n is 0, 1 or 2; A is oxygen or sulfur; R.
sup.
1 and R.
sup.
4 independently are hydrogen, C.
sub.
1 -C.
sub.
8 alkyl, C.
sub.
2 -C.
sub.
8 alkenyl, C.
sub.
3 -C.
sub.
8 cycloalkyl, C.
sub.
1 -C.
sub.
8 hydroxyalkyl; R.
sup.
2 and R.
sup.
3 independently are C.
sub.
1 -C.
sub.
8 alkyl, C.
sub.
2 -C.
sub.
8 alkenyl, C.
sub.
3 -C.
sub.
8 cycloalkyl, C.
sub.
1 14 C.
sub.
8 hydroxyalkyl, C.
sub.
1 -C.
sub.
8 dihydroxyalkyl, C.
sub.
2 -C.
sub.
8 alkoxyalkyl, C.
sub.
3 -C.
sub.
8 alkoxy(alkoxyalkyl), C.
sub.
1 -C.
sub.
8 aminoalkyl wherein the amino group is NR.
sup.
5 R.
sup.
6 in which B.
sup.
5 and R.
sup.
6 independently are hydrogen, C.
sub.
1 -C.
sub.
8 alkyl, C.
sub.
7 -C.
sub.
14 phenylalkyl or R.
sup.
5 and R.
sup.
6 together with the N atom form a 5 or 6 membered heterocycle selected from the group consisting of piperidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperazinyl or N'-C.
sub.
1 -C.
sub.
4 -alkylpiperazinyl; and X, W, Z and U independently are hydrogen, C.
sub.
1 -C.
sub.
8 alkyl, C.
sub.
1 -C.
sub.
8 alkoxy, CF.
sub.
3, cyano, nitro or halo, (i.
e.
fluoro, chloro or bromo) provided that at least two of X, W, Z and U are hydrogen or X and W or W and Z or Z and U together with the phenyl group to which they are attached form a naphthyl or benzoxadiazole group, and pharmaceutically acceptable salts thereof.
The preferred compounds of this invention are those represented by the general structural formula (I) wherein: n is 0 or 1; A is oxygen; R.
sup.
1 and R.
sup.
4 independently are hydrogen or C.
sub.
1 -C.
sub.
8 alkyl; R.
sup.
2 and R.
sup.
3 independently are C.
sub.
1 -C.
sub.
8 alkyl or C.
sub.
1 -C.
sub.
8 aminoalkyl wherein the amino group is NR.
sup.
7 R.
sup.
8 in which R.
sup.
7 and R.
sup.
8 independently are hydrogen, C.
sub.
1 -C.
sub.
8 alkyl or C.
sub.
7 -C.
sub.
14 phenylalkyl; and X, W, Z and U independently are hydrogen, C.
sub.
1 -C.
sub.
8 alkoxy, CF.
sub.
3, cyano, nitro or halo provided that at least two of X, W, Z and U are hydrogen
|
| Related patents |
|
|
Ace inhibitors in macular degeneration
OF THE INVENTION The novel method of treatment of senile macular degeneration of this invention comprises the administration to a patient in need of such treatment of ...
|
|
|
Derivatives of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonines and -1,4-benzoxazonines, processes for their production and their use as pharmaceuticals
We claim: 1. 2,3,4,5,6,7-Hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds, of the formula ##STR15## wherein: R.sub.1 is hydrogen or C.sub.1 -C....
|
|
|
Novel benzylalcohol derivatives and processes for preparing the same
What we claim is: 1. A compound of the formula: ##STR11## wherein R is a lower alkyl group having 1-4 carbon atoms, or a pharmaceutically acceptable acid addition salt ...
|
|
|
Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents
What is claimed is: 1. A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory ...
|
|
|
1-arylsulphonyl-2-piperidinone derivatives, process and intermediates for the preparation thereof, their application as antispasmodics and compositions containing them
What is claimed is: 1. The compound of formula (I): ##STR11## in which R represents the radical ##STR12## in which R.sub.1 at any position on the benzene ring represents ...
|
|
|
Dihydropyridine derivatives and pharmaceutical composition thereof
OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (I) ##STR2## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or ...
|
|
|
1-[2-(1H-inden-3-yl)ethyl]-4-(naphth-1-yl)piperazine derivatives, their preparation and their application in therapeutics
We claim: 1. A compound of the formula: ##STR6## in which X represents a hydrogen atom, a C.sub.1 -C.sub.3 alkoxy group or a cyclopropylmethoxy group, and Y represents a ...
|
|
|
Use of fedotozine in the treatment of functional states of intestinal obstructions
We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering a therapeutically effective dose of (+)-1-[(3,4,5-trimethoxy)...
|
|
|
Manufacture of pharmaceutical dosage forms
OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ingestion which are advantageous in a number of particulars over ...
|
|
|
Device comprising liner for protecting fluid sensitive medicament
OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various delivery devices provided by the invention and which examples are not to be ...
|
|
|
Vasodialators 
